Vera Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
Vera Therapeutics, a late clinical-stage biotechnology company, announced its participation in the Goldman Sachs 45th Annual Global Healthcare Conference.
The event will occur from June 10-13, 2024, at the Loews Miami Beach Hotel.
CEO Marshall Fordyce, M.D., will present on June 12 at 10:40 AM EDT, and the management team will engage in one-on-one investor meetings.
- Participation in the prestigious Goldman Sachs 45th Annual Global Healthcare Conference could enhance Vera Therapeutics' visibility in the investment community.
- CEO presentation scheduled, signaling leadership engagement and potential new insights into the company's progress and future plans.
- One-on-one investor meetings may lead to new investment opportunities and partnerships, potentially boosting stock value.
- No new clinical trial data or financial updates provided in the announcement, leaving investors without fresh insights into the company's performance.
- Participation in conferences often incurs costs that may affect the company's short-term financials.
- Absence of concrete outcomes from the conference participation leaves uncertainty about tangible benefits for shareholders.
BRISBANE, Calif., June 07, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s management team will participate in the Goldman Sachs 45th Annual Global Healthcare Conference, taking place June 10 – 13, 2024 at the Loews Miami Beach Hotel, Miami Beach, FL.
Presentation Details:
Date: Wednesday, June 12, 2024
Time: 10:40 AM EDT
Presenter: Marshall Fordyce, M.D., Chief Executive Officer
The management team will also participate in one-on-one investor meetings.
About Vera
Vera Therapeutics is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases. Vera’s mission is to advance treatments that target the source of immunological diseases in order to change the standard of care for patients. Vera’s lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases, including IgAN, also known as Berger’s disease, and lupus nephritis. In addition, Vera is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. Vera is also developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus (BKV), a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. Vera retains all global developmental and commercial rights to atacicept and MAU868. For more information, please visit www.veratx.com.
For more information, please contact:
Investor Contact:
Joyce Allaire
LifeSci Advisors
212-915-2569
jallaire@lifesciadvisors.com
Media Contact:
Mari Purpura
LifeSci Advisors
mpurpura@lifesciadvisors.com
FAQ
When will Vera Therapeutics participate in the Goldman Sachs 45th Annual Global Healthcare Conference?
Who will represent Vera Therapeutics at the Goldman Sachs 45th Annual Global Healthcare Conference?
Where is the Goldman Sachs 45th Annual Global Healthcare Conference being held in 2024?
What is the stock symbol for Vera Therapeutics?
What is the primary focus of Vera Therapeutics?
